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ABSTRACT
The dopamine transporter (DAT) is a plasma membrane protein that clears extraneuronal
dopamine (DA) and thus controls the spatio-temporal dynamics of dopaminergic
neurotransmission.

Also, DAT is the major target for psychostimulant substrates,

amphetamine (AMPH) and methamphetamine (METH), and psychostimulant uptake
blocker, cocaine (COC). DAT is a phosphoprotein with both the N- and C-termini facing
toward the cytosol, with multiple phosphorylation sites on the N-terminus. DAT has a
closely spaced 6-serine cluster on the distal N-terminus that is phosphorylated in a
protein kinase C (PKC)-dependent manner and a recently identified proline-directed site,
Thr (T) 53, that is phosphorylated in vitro by the MAP kinases ERK, JNK and p38.
Current studies indicate that COC and AMPH impact DAT regulatory properties
including uptake activity and surface expression. Although the mechanism of drug action
on DAT is not completely known, phosphorylation conditions of DAT have been found
to be associated with altered surface expression and activity of DAT. In this study, we
examined the effect of several psychostimulant drugs on the phosphorylation of DAT
using a newly developed phospho-specific antibody against phosphorylated T53 (pT53)
on DAT. A detailed analysis of pT53 on DAT was performed in LLC-PK1 cells
expressing rat DAT (rDAT), rat striatal synaptosomes and in vivo in male SpragueDawley rats. Our studies revealed psychostimulant substrates but not uptake blockers
significantly stimulated pT53. Pretreatment with COC blocked the AMPH stimulation of
pT53 indicating that AMPH stimulates pT53 in a DAT-dependent manner. In rat striatal
synaptosomes, METH-stimulation of pT53 was very fast; occurring within 60 sec.
! xii!
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Subcutaneous injections of METH in rats stimulated pT53 in a time-dependent manner.
Our study demonstrates that the proline-directed phosphorylation site, pT53 is subject to
differential regulation by psychostimulant drugs. Prolyl cis-trans isomerase, Pin1
catalyzes the cis-trans isomerization of pThr-Pro peptides allowing the dephosphorylation
by conformation-specific phosphatases. We investigated the regulation of pT53 by Pin1
using Juglone (Jug), a small molecule inhibitor of Pin1. Treatment with Jug in LLC-PK1
rDAT cells and rat striatal synaptosomes revealed significant stimulation of pT53. Jug
treatment enhances [3H]DA efflux from rat striatal synaptosomes. ELISA indicated
interaction between the N-terminus of DAT and Pin1. This is the first evidence of DAT
regulation by Pin1. Our study demonstrates the regulation of DAT pT53 by Pin1 and
psychostimulant drugs under physiological conditions.
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CHAPTER I
!

INTRODUCTION
!

Neurotransmission
!

The brain governs physiological and psychological processes of the human body
through a highly complex and coordinated network composed of billions of neurons.
Each neuron communicates with other neurons by a process known as neurotransmission.
Neurotransmission occurs at specialized neuronal junctions called synapses. This process
involves the release of neurotransmitter from the presynaptic neuron, which is recognized
by the receptors on the surface of the postsynaptic neuron.
Synaptic vesicles that serve as the storage pool of the neurotransmitters are
docked at the active zones of presynaptic neuronal membranes and primed for the release
of neurotransmitter. Neurotransmission occurs in response to the depolarization of the
presynaptic neuronal membrane upon arrival of the action potential. The action potential
that originates in the cell body of the neuron travels down the axon terminal and opens
Ca2+ channels. The increase in Ca2+ triggers the fusion of the primed synaptic vesicles
with the neuronal membrane to release their contents into the synaptic cleft. The released
neurotransmitter is sensed by the receptors on the postsynaptic neuron propagating the
signal to the connecting neuron. Neurotransmission is terminated by clearance of the
neurotransmitter from the synapse in one or more of the following ways- enzymatic
! 1!
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degradation, diffusion and or re-uptake of the released neurotransmitter in to presynaptic
neuron by neurotransmitter-specific transporter proteins or re-uptake into a neighboring
glial cell [1].
Dopamine and dopaminergic system
!

Dopamine (DA) is synthesized in dopaminergic neurons from tyrosine. Tyrosine
is also the precursor of other catecholamine neurotransmitters like norepinephrine (NE)
and epinephrine. Initially DA was only considered as a mere precursor of NE and
epinephrine. Later, neurotransmitter properties of DA were demonstrated and since then
DA is regarded as a neurotransmitter which controls movement, reward-seeking
behavior, emotion and cognition [2,3]. Dopaminergic neurons are present in the ventral
tegmental area (VTA), the substantia nigra and the arcuate nucleus of the hypothalamus
regions of the brain. There are four dopaminergic pathways, mesocortical, mesolimbic,
nigrostriatal, and tuberoinfundibular (Fig.1). Among the four pathways, the mesolimbic
pathway that connects the VTA of the mid brain to the nucleus accumbens in the striatum
is associated with a reward circuit and known to be involved in the drug addiction
process [4].
Dopamine transporter
!

Dopaminergic neurotransmission is terminated by various processes- uptake of
DA by glial cells and dopaminergic neurons, degradation of DA by catechol-O-methyl
transferase (COMT) and monoamine oxidase (MAO). The major process of
dopaminergic signaling termination occurs by transporter proteins localized to the
presynaptic neuronal membrane. DA is rapidly transported into the presynaptic neuron by
! 1!
!

Figure 1. The four dopaminergic pathways
Dopaminergic neurons extend from the ventral tegmental area (VTA), substantia nigra
and mesobasal hypothalamus to the nucleus accumbens, prefrontal cortex, striatum and
base of the hypothalamus. These neuronal projections form the mesolimbic, mesocortical,
nigrostriatal, and tuberoinfundibular pathways.
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Image adapted from Okinawa Institute of Science and Technology with permission
Figure 1. The four dopaminergic pathways
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transporters localized to the presynaptic neuronal membrane. The transporters are
neurotransmitter-specific dopamine transporter (DAT) for DA, serotonin transporter
(SERT) for serotonin, norepinephrine transporter (NET) for norepinephrine [5].
Primary target for psychostimulants
!

Psychostimulants like methamphetamine (METH), d-amphetamine (AMPH)
(collectively referred to as amphetamines) and cocaine (COC) (Fig.3), have been a major
threat to society. The strong reinforcing properties and the abuse potential of these drugs
indicate the requirement for development of an effective medication to treat drug
addiction. These psychostimulant drugs affect the neural circuitry and increase cravings
for repeated drug use leading to addiction [6]. Understanding the molecular mechanisms
of psychostimulant drugs for the development of therapeutic approach has been an active
area of research.
The psychostimulants are known to elicit their actions primarily by altering
dopaminergic homeostasis in the brain (Fig.2). In 1980s, a few studies implicated that
dopamine-containing neurons in the forebrain projections and the ventral tagmentum of
the brain region are crucial for the reinforcing properties of psychostimulant drugs like
COC and AMPH [7]. Though the role of dopaminergic signaling in psychostimulant
abuse was not completely established, pathology of the dopamine system was predicted
as a potential target for psychostimulant action [4], [7]. The requirement of DAT and DA
signaling in psychostimulant action was strongly established with the development of
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Figure 2. Representation of a dopaminergic synapse under physiological and pathological
states
A. Under physiological conditions, DA is recycled back into the presynaptic neuron by
DAT where DA is transported into vesicles by VMAT and stored. B. In the presence of
the DAT blocker, cocaine, the reuptake of DA into presynaptic neuron is prevented
resulting in buildup of DA at the synapse. C. Amphetamines are DAT substrates, once
inside the neuron, they also get transported via VMAT into vesicles and cause the release
of DA increasing the cytosolic concentration of DA and cause non-vesicular release of
DA via DAT.
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A

B
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Image courtesy, R. A. Espana and S. R. Jones, 2013 Presynaptic dopamine modulation by
stimulant self-administration. Front. Biosci. (Schol. Ed)., vol. 5, pp. 261–76, with
permission [8]
Figure 2. Representation of a dopaminergic synapse under physiological and pathological
states

! 6!
!

Figure 3. Chemical structures of dopamine transporter substrates and cocaine
Representation of chemical structures of dopamine transporter (DAT) substrates:
dopamine, amphetamine, methamphetamine, MPP+ and DAT blocker: cocaine
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Figure 3. Chemical structures of dopamine transporter substrates and cocaine
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DAT knock out (KO) mice. Homozygous DAT KO mice displayed decreased DA uptake
and highly compromised ability to clear the extraneuronal DA consistent with increased
spontaneous locomotor activity [9]. This further led to the ‘dopamine hypothesis’,
according to which, cocaine first binds to DAT and blocks DA uptake (Fig.2), which
results in potentiation of dopaminergic neurotransmission in the limbic pathways. This
ultimately leads to reinforcement of the behavior that is associated with the molecular
events of cocaine binding and uptake inhibition [10].
COC is non-transportable through DAT [11], the psychostimulants and other
therapeutic drugs that belong to this class are called blockers. DAT blockers that do not
induce cocaine-like behavioral patterns such as benztropine (BZT) are termed atypical
uptake blockers [12]. Along with the inhibition in DA uptake, DA receptors are also
implicated in the reinforcement of COC [7].
Amphetamines are also a prescribed medication for ADHD and depression.
Amphetamines act in a complex fashion to impact DA signaling. In addition to uptake
inhibition of DAT [13], AMPH also gets transported via DAT into the presynaptic
neuron. Once inside the presynaptic neuron, AMPH causes reverse transport of DA via
DAT (Fig.2). This process is also referred to as efflux. In addition, at higher
concentrations, amphetamines are also known to diffuse through the membrane due to
their hydrophobic nature. Pretreatment with COC blocks AMPH-stimulated DA efflux
indicating that DAT-mediated entry of AMPH is required for the efflux mechanism [14,
15]. The mechanism of DAT transport reversal by AMPH is proposed to occur by an
exchange diffusion model. According to this model, AMPH gets transported into the
presynaptic neuron in a Na+-dependent manner to cause reverse transport of DA through
! 9!
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DAT. AMPH also contributes to the increased synaptic DA concentration by depleting
the secretory vesicle stores of DA. In addition, AMPH also inhibits MAO preventing the
oxidation and inactivation of DA [16]. These mechanisms result in the increase in the
cytosolic concentration of DA favoring the AMPH-stimulated efflux and contributing to
oxidative damage. In addition to psychostimulant drugs, DAT also serves as a gateway
for several environmental toxins like MPP+, which is derived from MPTP (1-methyl-4phenyl-1,2,3,6-tetrahydropyridine) by MAO [17][18] (Fig.3).
Structure
!

DAT, NET, and SERT along with transporters for other solutes like glycine and
GABA are encoded by genes of the SLC6 (Solute Carrier 6) family. The members of the
SLC6 family are expressed in a wide range of tissues with major distribution in the
central nervous system (CNS) where they function to maintain homeostasis of
neurotransmitters. These are secondary active transporters that utilize the electrochemical gradient generated by Na+/K+ ATPase to drive the symport of neurotransmitter
and Na+ [19] [5] [20] [21].
The cDNA of rat DAT was first cloned, transiently expressed and characterized
for DA uptake activity in HeLa cells [22]. Human DAT (hDAT) is a 620 amino acid
protein while rat DAT (rDAT) is comprised of 619 amino acids, and both contain 12
transmembrane (TM) domains with both N and C termini facing towards the cytosol. The
primary sequence of DAT has revealed sites for glycosylation on the extracellular loop
which were later observed to have a role in regulating function, surface expression [20]
[23]. Though the hydrophobicity analysis and mutation studies revealed 12 TMs and the
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glycosylation sites, the three dimensional structure of DAT was not known until the
crystallization of a bacterial homologue, a leucine transporter (Leu T) from Auifex
aeolicus [24]. This bacterial homologue shares 20% sequence homology with DAT. Leu
T crystal structure displays a pseudo-symmetrical arrangement of TMs 1-5 and TMs 6-10
with TMs 1, 3, 6 and 8 constituting the core of the transporter forming the substrate
translocation pathway. In addition to the information from the Leu T crystal structure,
drosophila DAT (dDAT) crystal structure was recently reported [25].
DAT is proposed to function by an alternating access mechanism [26] in which
DAT undergoes a series of conformational changes from an outward-facing
conformational state to an inward-facing conformation (Fig.4). The different
conformations of DAT are stabilized by different gates, which allow access to DAT from
either the extracellular or intracellular side [27]. The outward facing conformation of
DAT in which the extracellular gate is open, allows the substrate to bind from the
extracellular side. The extracellular gate is formed by a salt bridge between the amino
acids R85 on TM1 and D476 on TM10. The intracellular gate formed by R60 on the Nterminus and D436 on TM8 opens to form the inward-facing state [24][28]. This
conformation allows the release of substrate to the intracellular milieu. The substratebound transporter with both the extracellular and the intracellular gates closed results in
an occluded conformation.
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Figure 4. Alternating access model of SLC6 transporters
The figure depicts the series of conformational states in an alternating access model of
SLC6 transporters. The outward-facing conformation allows substrate and sodium ion
binding to the transporter. The occluded conformation is then followed representing a
state in which, the extracellular and the intracellular gates are closed. The inward facing
conformation with the intracellular gate open allows the release of the substrate and the
co-transported ions into the cytosol.
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Image courtesy, A. S. Kristensen, J. Andersen, T. N. Jørgensen, L. Sørensen, J. Eriksen,
C. J. Loland, K. Strømgaard, and U. Gether, 2011 SLC6 neurotransmitter transporters
structure, function, and regulation. Pharmacol. Rev., vol. 63, pp. 585–640, with
permission [27].
Figure 4. Alternating access model of SLC6 transporters
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All the gating residues are conserved in the SLC6 transporters [24]. Mutation of the
gating residues in DAT has been shown to impact the conformational states of the
transporter [28] [29]. The intracellular gating resides R60 and D436 in DAT, when
mutated to R60A and D436A displayed significant decreases in Vmax for [3H]DA uptake
[28]. The surface expression of both the mutants were comparable to WT DAT
suggesting the decreased uptake was not due to altered surface expression but due to the
impairment of the intracellular gating residues [28]. The Leu T crystal structure revealed
the interaction of the intracellular gating residue, R60 with Y335 in TM6. Y335A DAT
displayed reduced Vmax with no loss in surface expression compared to WT DAT
indicating its prominent role in stabilizing the intracellular gate and hence DAT function
[29].
The role and requirement of the following residues R60, D436 and Y335 in the
intracellular gating mechanism has been further substantiated by Zn2+ coordination
experiments. Zn2+ interacts with H193, H375 and E396 to stabilize the outward facing
conformation of DAT [30]. The decreased uptake activities of R60A, D436A and Y335A
DATs were rescued in the presence of Zn2+[28], [29]. This demonstrates the ability of
Zn2+ to stabilize the outward facing conformation and facilitate the uptake activity in
intracellular gate impaired DAT mutants.
In addition to the role of Zn2+ in stabilizing the outward open conformation of
DAT, the dDAT crystal structure revealed the presence of cholesterol, which is
hypothesized to stabilize DAT in an outward-open conformation [25]. This indicates that
several factors play a role in stabilizing different conformational states of DAT. Also
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reported in dDAT structure was a kink in TM12 that resembles a latch facing away from
the transporter which is predicted to potentially regulate DAT function [25].
The cytoplasmic tails, both N- and C-termini, are much shorter in both dDAT and
the bacterial homologue Leu T leading to the lack of a resolved structure for these tails
[24], [25]. Both tails are sites for several post-translational modifications and regulate
various characteristics of the transporter while serving as sites of interaction for many
binding partners.
DAT interaction partners
!

DAT has been shown to interact and form complexes with various proteins, which
in turn affect the function, phosphorylation, trafficking and, subcellular localization of
DAT (Fig.5). DAT is a dynamic membrane protein that trafficks to and from the plasma
membrane. Some of the proteins that interact with DAT include synaptic vesicular
plasma membrane proteins and enzymes like PP2A, PKC β, RACK, Hic-5, synaptogyrin3, VMAT2, Syntaxin 1A (Syn 1A) [31]–[34].
Syn 1A, a SNARE protein was observed to decrease DAT uptake activity along
with decreased surface expression in a heterologous system co-expressing DAT and Syn
1A [35]. In addition, Syn 1A was also found to enhance AMPH-stimulated DA efflux
[36]. This indicates the role of Syn 1A in regulating DAT function under physiological
conditions and drug abused states. Membrane micro domain marker, Flotillin 1 (Flot 1)
was recently identified as a protein required for PKC-triggered endocytosis of DAT that
also favors AMPH-induced efflux in DA primary neurons without affecting DA uptake
[37]. Yeast two-hybrid analysis and GST pull-down assays confirmed Rin (Ras like in
! 15!
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Figure 5. Representation of interaction partners of the dopamine transporter
Figure represents the dopamine transporter embedded in a lipid bilayer with the posttranslational modifications on both N-terminal and C-terminal tails. The interaction
partners of DAT – Rin (blue), CaMK (green), Flotilin1 (dark green) are depicted.
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Image courtesy, R. A. Vaughan and J. D. Foster, 2013 Mechanisms of dopamine
transporter regulation in normal and disease states. Trends Pharmacol. Sci., vol. 34, no.
9, pp. 489–96, [38].
Figure 5. Representation of interaction partners of the dopamine transporter
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neurons) as a DAT interacting protein in a PKC regulated manner and required for PKCtriggered endocytosis of DAT [39]. AMPH is also known to impact the surface
expression of DAT.
AMPH-induced internalization of DAT is observed in both heterologous
expression system and rat striatal synaptosomal preparations [40]. Interestingly, in the
early treatment times (60 sec) [41], amphetamines cause rapid increase in the surface
expression of DAT in a heterologous expression system. Methamphetamine (METH)
exposure redistributes dopamine from vesicles to the cytoplasm in dopamine neuronal
cultures contributing to the formation of reactive species [42] and also triggers DAT
complex formation [43]. Involvement of many players in DAT interaction and regulation
appears that the system may have evolved with several backup or alternate mechanisms
for monitoring DAT activity and surface expression under normal as well as under
diseased or drug abused states accordingly.
Regulation of DAT
Phosphorylation
!

DAT has been shown to be regulated by various protein kinases including PKC,
ERK, PKA, and CaMKII [44]–[47] with PKC regulation of DAT being the most
extensively studied. In rat striatal tissue and cultured cells stably expressing hDAT or
rDAT, both PKC activation with phorbol 12-myristate 13-acetate (PMA) [45] and
inhibition of phosphatases with okadaic acid (OA) increases phosphorylation of DAT in a
dose-dependent manner [45], [48]. PKC stimulation in native tissue as well as in
heterologous
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Figure 6. Schematic representation of the rat dopamine transporter
The figure shows the rat dopamine transporter with 12 transmembrane domains
connected by extracellular and the intracellular loops with both N- and C-termini facing
towards the cytoplasm. Known in vivo phosphorylation sites are represented in big lightblue circles. Also depicted, in small light-blue circles, are predicted phosphorylation
sites. Depicted in green is epitope 16 on the N-terminus and the palmitoylation site, in
brown, on the C-terminus.

! 19!
!

Figure 6. Schematic representation of the rat dopamine transporter
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expression systems have shown decreased Vmax with no change in affinity [45], [49]–
[51]. Down regulation of DAT activity in the presence of PKC activation is associated
with decreased surface expression of DAT. PKC activation was demonstrated to localize
DAT to recycling endosomes where it colocalizes with transferrin receptor [52]. A Cterminal subdomain FREKLAYAIA, spanning amino acids 587-596 of DAT (Fig.6) was
later implicated to be required for constitutive endocytosis and PKC-stimulated down
regulation of DAT in PC12 cells and primary midbrain neurons. The sequence
FREKLAYAIA is conserved among the other neurotransmitter transporters and was
demonstrated to be required for a fellow SLC6 transporter, NET [53]. Further studies on
this subdomain led to a proposed model that the residues in the first half of the
FREKLAYAIA spanning residues 587-590 might act as a braking mechanism to control
basal endocytosis, with PKC activation releasing the break resulting in enhanced
endocytosis [54]. Although PCK-stimulated down regulation of DAT activity was
thought to be mediated through phosphorylation of DAT, truncation of distal N-terminal
serines displayed no effect on PKC-stimulated internalization, ruling out the notion of
PKC phosphorylation of DAT as an endocytosis requirement and implicating the
potential involvement of another protein [55].
Mitogen activated protein kinases (MAPK) have been shown to regulate DAT
function and surface expression. Inhibition of MAPK with U0126 or PD98059
significantly decreased DAT function in both rat striatal synaptosomes and in HEK 293
cells stably expressing DAT. The decrease in uptake activity in MAPK-inhibited
conditions was associated with enhanced DAT internalization [56]. Later in 2007 another
study revealed that DA receptor agonist, quinpirole, increased DAT uptake activity in
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N2A and EM4 cells (HEK 293 cells stably expressing macrophage scavenging receptor).
The quinpirole treatment also stimulated the activated forms of MAPK and
phosphoinositide-3 kinase (PI-3 kinase). Inhibition of both these kinases abolished the
agonist-stimulated increase in DAT uptake activity and surface expression. Acute
treatment with DA receptor agonists increased DAT surface expression while longer
treatment times increased internalization [57].
Metabolic [32P] labeling and phosphoamino acid analysis in rat striatal slices and
DAT expressing cell systems have narrowed down the PKC phosphorylation sites to the
N-terminal 6-serine cluster with a majority of the phosphorylation and a threonine with a
faint phosphorylation signal at the distal N-terminus of DAT [58] (Fig.6) . Though PKC
was the extensively studied kinase for DAT phosphorylation, in vitro kinase assays with
recombinantly

expressed

N-terminus

of

DAT

(N-DAT)

showed

increased

phosphorylation with proline-directed kinases: ERK, PKC, P38, JNK. Gorentla et al
identified the threonine as a proline-directed phosphorylation site on the DAT Nterminus, T53 [44]. This proline-directed site is also found conserved in human DAT as a
serine. The evidence that has accumulated over years that has shown DAT to be
phosphorylated by different kinases triggered research in trying to understand the impact
of the phosphorylation on function, surface expression and other properties of DAT.
DAT phosphorylation is also affected by psychostimulants like AMPH and
METH but not COC. In vitro and in vivo treatments of amphetamines stimulate
phosphorylation of DAT, which is abolished by PKC inhibitors. This phosphorylation
was found to be at the serine cluster at the distal N-terminus of DAT as Δ21 DAT, a
truncation mutant which lacks the first 21 residues had no basal or AMPH-stimulated
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phosphorylation [59]. Some studies have shown that the N-terminus [60] and
phosphorylation on the N-terminus of DAT are required for AMPH-stimulated efflux
[61]. CaMKII interaction with the C-terminus of DAT has been demonstrated in both
heterologous expression systems and in dopaminergic neurons. Interaction of CaMKII
with DAT C-terminus facilitates phosphorylation of the N-terminus of DAT which is
required for AMPH-stimulated DA efflux. Inhibition of CaMKII or mutation of Nterminal phosphorylation sites on DAT attenuated both AMPH-stimulated DA efflux and
MPP+ efflux suggesting the importance of N-terminal phosphorylation for the efflux
mechanism of AMPH [62,63]. PKC activation by PMA increases DAT-mediated efflux
indicating either a direct role for DAT phosphorylation in efflux or attraction of an
interacting partner that facilitates efflux [64]. Though AMPH induces efflux and
stimulates DAT phosphorylation, METH has been observed to have a stronger effect than
AMPH [65]. All these studies imply that AMPH-stimulated DAT phosphorylation could
be a key mechanism responsible for the psychostimulant action and of the strong
reinforcement characteristic of this drug.
Proline-directed phosphorylation
!

Phosphorylation of a serine/threonine preceding a proline (proline-directed
phosphorylation site) renders an additional structural change to the protein [66] and is
predicted to impact the structure and function of the protein (Fig.7). Prolyl isomerases
(PPIases) catalyze the conversion of cis/trans conformation of Ser/Thr-Pro peptides. Pin1
(Protein interacting with NIMA), a parvulin family member, specifically catalyzes the
isomerization of pSer/Thr-Pro motifs [67], [68]. The cis to trans isomerization rate of
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Figure 7. Isomerization of proline-directed phosphorylation sites by Pin1
Peptidyl prolyl isomerase, Pin1, catalyzes the cis-trans isomerization of phosphorylatedThr-Pro (pT-P) allowing the dephosphorylation by conformation-specific phosphatases.
Pin1 stabilizes the cis and trans conformations of pT-P of the protein, which are predicted
to display different functional characteristics.
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Figure 7. Isomerization of proline-directed phosphorylation sites by Pin1
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pSer/Thr-Pro-containing peptides is intrinsically slow and requires the activity of the
isomerases.
T53 is the only reported proline-directed phosphorylation site on the DAT Nterminus that is phosphorylated in vitro by proline-directed kinases such as ERK, JNK
and P38 [44]. The importance of T53 in regulating DAT function was recently
demonstrated [69]. The role of N-terminal residues in regulating DAT function was also
reported in other studies [70] [71].
Pin1-catalyzed

cis/trans

isomerization

is

crucial

as

it

allows

the

dephosphorylation by conformation-specific phosphatases such as PP2A (Fig.7). This
was demonstrated in the hyperphosphorylated tau protein. Pin1 facilitates the
dephosphorylation of hyperphosphorylated tau protein by PP2A showcasing the presence
of a post-phosphorylational regulatory step that restores the function [72] [73]. This
indicates an additional regulatory step for proline-directed phosphorylation sites that
might dictate DAT function or subcellular localization.
Purpose of the current study
!

DAT phosphorylation and function has been shown to be regulated by
psychostimulant drugs [64,74], [76–78]. Previous studies from our lab indicated a
differential regulation by psychostimulant drugs on DAT function and phosphorylation
[74], [77]. While direct regulation of DAT by PKC has been reported [45], [78] , MAPK
regulation of DAT via dopamine 2 receptors (D2Rs) was reported [56], [57]. In this study
we specifically investigated the effect of psychostimulant drugs and DA on pT53 in a
heterologous expression system, rat striatal synaptosomes and in vivo. These results will
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help in understanding the role of psychostimulant action on pT53 and direct regulation of
DAT by MAPK. Also, we designed our experiments to test for post-phosphorylational
regulation at pT53 and its effect on DAT function using the Pin1 inhibitor, juglone (Jug).
These results will increase our understanding of the additional pathways regulating DAT
phosphorylation and function.
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CHAPTER II
!

MATERIALS AND EXPERIMENTAL METHODS
!

Materials
Animals
!

Male Sprague Dawley rats (175-300g) were purchased from Charles Rivers Laboratories
(Wilmington, MA) and maintained in compliance with the guidelines established by the
University of North Dakota Institutional Animal Care and Use Committee and the
National Institutes of Health.
Reagents
!

Protein A Sepharose beads, and High Range Rainbow Molecular Weight Markers were
purchased from GE Healthcare Life Sciences (Piscataway, NJ). (-)-Cocaine, damphetamine, (+)-methamphetamine, dopamine, and benztropine were purchased from
Sigma Aldrich (St. Louis, MO). Phorbol-12 myristate-13 acetate (PMA) and Okadaic
Acid (OA), and Juglone were purchased from Calbiochem/EMD Biosciences (La Jolla,
CA). Ez-Link Sulfo-NHS-SS-Biotin and immobilized Neutravidin Beads were obtained
from Pierce Chemical (Rockford, IL). Complete Mini Protease Inhibitor was purchased
from Roche Applied Science (Indianapolis, IN). All other chemicals were purchased
from Sigma Aldrich (St. Louis, MO) or Fischer Scientific (Pittsburg, PA).
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Equipment
!

Centrifuges
!

The Beckman Avanti J-25 was used for synaptosomal preparation. The Beckman J6-MI
swinging bucket rotor was used for crosslinking Protein A Sepharose beads. A
refrigerated Beckman Microfuge R or a bench top Microfuge were used to pellet cells
and for immunoprecipitations.
Electrophoresis
!

SDS-PAGE was performed using Bio-Rad Mini-Protean III electrophoresis apparatus and
proteins transfers to PVDF were performed using Bio-Rad Mini trans blot electrophoresis
transfer cell. A Gibco/BRL Life Technologies 250 EX power supply was used to control
both Bio-Rad electrophoresis and Bio-Rad protein transfer apparatus.
Cell culture and Miscellaneous
!

LLC-PK1 (Lewis lung carcinoma porcine kidney) cells stably expressing rDAT were
maintained in a Nuair 2700-30 water-jacketed CO2 incubator and handled in a Nuair
Class II type A/B3 laminar flow hood. Synaptosomal preparations for uptake and efflux
assays were handled and washed using the Brandel Tissue Harvester.
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Experimental methods
!

T53 Phosphorylation assay in rDAT LLC-PK1 cells
!

LLC-PK1 cells stably expressing WT rDAT were maintained in α-minimum essential
medium supplemented with 10% fetal bovine serum, 2 mM L- glutamine, 200 µg/ml
G418, and 1 X penicillin/streptomycin in an incubation chamber with 5% CO2, 95% O2 at
37°C. Cells were plated in either 6 or 12 well plates and grown to 80% confluence. Cells
were washed twice with 2 ml or 1 ml of Kreb’s-Ringer HEPES (KRH) buffer (25 mM
HEPES, 125 mM NaCl, 4.8 mM KCl, 1.2 mM KH2PO4, 1.3 mM CaCl2, 1.2 mM MgSO4,
5.6 mM glucose, pH 7.4). Cells were treated with 10 µM d- amphetamine, BZT, 100 µM
cocaine, 1 µM OA, 1 µM PMA or vehicle for 30 min at 37° C. BZT, d-amphetamine, (-)cocaine, were prepared in distilled/deionized water, OA and PMA were prepared in
DMSO with a final DMSO concentration maintained below 1%. Each condition was
performed in duplicate. Cells were immediately placed on ice and washed with ice-cold
KRH twice to remove the drugs. 300 µl of RIPA with protease inhibitor was added to
each well and solubilized on ice for 20 min with shaking. The cell lysates were
centrifuged at 15,000 x g for 30 min at 4°C. The supernatants were collected and
subjected to SDS-PAGE and the proteins were transferred to PVDF membrane. The
membrane was immunoblotted with a phospho-specific antibody (1:1000 dilution in 3%
BSA blocking buffer) developed against T53 on DAT (pT53 Ab) [69]. Total DAT in the
corresponding samples was analyzed by immunoblotting samples with DAT specific
monoclonal antibody (1:1000 dilution in 3% BSA blocking buffer) developed against
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epitope 16 on the N-terminus on DAT (MAb16) [79]. Parental cells not expressing DAT
were used as negative control.
Striatal synaptosomal preparation
!

Striatal synaptosomes were prepared using male Sprague Dawley rats (175–300 g) [80].
In brief, animals were decapitated and the striatum was removed and weighed. The striata
were suspended in cold sucrose phosphate (SP) buffer (10 mM Na2HPO4, 0.32 M
sucrose, pH 7.4) and homogenized in a Teflon-glass homogenizer. The homogenate was
centrifuged at 3000 × g for 3 min at 4°C. The resulting supernatant was further
centrifuged at 17000 × g for 12 min at 4°C. The synaptosomal pellet was then resuspended in 0.32 SP buffer at 20 - 50 mg/ml of original wet weight (OWW) for
phosphorylation, uptake and efflux assays.
Phosphorylation, Immunoprecipitation and Immunoblot analysis in striatal synaptosomes
!

The synaptosomes were aliquoted into individual tubes and treated with vehicle or 10 µM
d-amphetamine,

(+)-methamphetamine,

dopamine,

5µM

juglone

or

indicated

concentration for 30 min or the indicated time at 30°C. Each condition was performed in
duplicate. The reaction was quenched by adding 1X sample buffer. The samples (50 µl)
were then immunoprecipitated with 50% slurry of pT53 Ab crosslinked protein A
sepharose beads at 4°C overnight and the beads were washed with IP buffer (phosphate
buffered saline, pH 7.4, plus 0.05% SDS, 0.1% Triton X-100) 4 times. The samples
eluted with 1X sample buffer at 37°C were subjected to SDS-PAGE electrophoresis and
transferred to PVDF. The immunoblot was then developed with MAb16 and pT53Ab for
total DAT levels and T53 phosphorylation, which were analyzed by densitometry.
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Dopamine uptake in striatal synaptosomes
!

For uptake assays, synaptosomes were treated with the indicated concentration of Jug or
vehicle prior to the assay for 30 min or indicated times at 30°C. The DMSO
concentration was maintained ≤ 1%. Transport was initiated by adding the synaptosomes
into tubes containing modified-Krebs phosphate buffer (126 mM NaCl, 4.8 mM KCl, 16
mM potassium phosphate, 1.4 mM MgSO4, 10 mM glucose, 1.1 mM ascorbic acid, and
1.3 mM CaCl2; pH 7.4), and [3H]DA to a final concentration of 1 nM. Uptake was carried
out in quadruplicate for 3 min at 30°C using 100 µM (−)-cocaine to define non-specific
uptake. Transport was stopped by the addition of 5 ml ice-cold SP buffer
and synaptosomes were harvested using a Brandel tissue harvester and Whatman GF/B
filters pre-soaked for 1 h in a 0.05% polyethyleneimine. Bound radioactivity was
quantified by liquid scintillation counting.
Efflux measurement in striatal synaptosomes
!

Synaptosomes were loaded with [3H]DA and incubated at 30°C for 5min. The extrasynaptosomal [3H]DA was removed by centrifugation of the synaptosomes at 17000 x g
for 12 min at 4°C and the supernatant was discarded. The synaptosomal pellet was
reconstituted with SP buffer and treated with indicated concentration of juglone for the
indicated times at 30°C. The synaptosomes were again spun down and the supernatant
was counted for radioactivity. Synaptosomes treated with 100 µM (−)-cocaine along with
juglone were considered non-specific efflux.
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In vivo analysis treatment of male Sprague-Dawley rats
!

Male Sprague-Dawley rats were subcutaneously injected with saline or METH (15
mg/kg) or COC (15 mg/kg) and the treated animals were caged separately. The animals
were decapitated after the treatment times and brain dissection was performed to remove
the striata which were placed in ice-cold SP buffer.
Striatal membrane preparation
!

Striatal membranes were prepared as described previously [59]. Briefly the membranes
were prepared using polytron and the homogenate was then centrifuged at 12000 x g for
12 min at 4°C. The membranes were then immunoprecipitated with protein-A sepharose
cross-linked with pT53 Ab overnight at 4°C to avoid any non-specific immunostaining.
The eluted sample is then subjected to SDS-PAGE followed by transfer to PVDF
membrane. The membrane is then immunoblotted with MAb16 to analyze for T53
phosphorylation (pT53).
ELISA
!

For the bait, recombinantly expressed and purified NDAT (10µg/ml) and commercially
available recombinant Pin1 (10µg/ml) from were coated on ELISA plates overnight at
4°C. The wells are then blocked with commercially available blocking solution at 4°C.
The solution containing prey either NDAT (10µg/ml) or Pin1 (10µg/ml) were incubated
in the appropriate well. The wells were incubated with MAb16 for NDAT or Pin1
polyclonal Ab and the interaction is detected by incubating with 1mg/ml PNPP substrate.
The absorbance was detected at 470 nm.
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Statistical analysis
!

The immunoblots were quantified by densitometry (LumiAnalyst software) and the
averaged values were statistically analyzed by student’s t-test or ANOVA. The graphs
were made in PRISM 3.0 software (Graphpad Software, San Diego CA.).!
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CHAPTER III
!

RESULTS
!

Physiological regulation of DAT T53 phosphorylation
!
!!!

To investigate the physiological regulation of pT53, LLC-PK1 cells stably

expressing rDAT were treated with the protein phosphatase inhibitor, okadaic acid (OA)
and PKC activator, PMA. Immunostaining with pT53 Ab revealed that T53 undergoes
basal phosphorylation and both OA (178 ± 15%, p<0.005) and PMA (140 ± 13%, p<0.05)
treatments stimulate pT53 (Fig.8). This indicates the dynamic regulation of T53 under
physiological conditions. Immunostaining with MAb16 displayed similar DAT levels in
the corresponding samples indicating that the treatment had no impact on total DAT
protein. The parental LLC-PK1 cells displayed no immunostaining with both pT53Ab and
MAb16 indicating the specificity of the antibodies to DAT [69].
OA dose response in rDAT LLC-PK1 cells
!

To identify the protein phosphatase that dephosphorylates pT53 on DAT, we
performed an OA dose response treatment in rDAT LLC-PK1 cells and the cell lysates
were analyzed with pT53 Ab or MAb16. An OA dose range of 0.1 nM to 1000 nM was
used to treat the cells. The pT53 level increased in a dose-dependent manner with small

! 35!
!

Figure 8. Kinase and phosphatase modulators stimulate pT53
Cells expressing rat DAT were treated with 1 µM OA, 1 µM PMA or vehicle (Basal) for
30 min at 37°C. Blots were probed with probed with pT53Ab (top) or MAb16 Ab
(bottom). The histogram indicates the quantification of pT53 signal induced by OA and
PMA (means ± S.E.), n=3, ***p value <0.0005, t-test. Solubilized DATs were resolved
by SDS-PAGE and transferred to PVDF. Blots were probed with pT53Ab or MAb16.
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Figure 8. Kinase and phosphatase modulators stimulate pT53

! 37!
!

Figure 9. Dose response of OA-stimulated DAT pT53
rDAT LLC-PK1 cells were treated with increasing doses of OA for 30 min at 30°C.
Solubilized DATs were resolved by SDS-PAGE and transferred to PVDF. Blots were
probed with pT53Ab (top) to detect phosphorylation and MAb16 (bottom) to detect total
DAT. The graph indicates T53 phosphorylation normalized to total DAT with respect to
the dose of OA. Arrows indicate the IC50 values of the specified phosphatases. n=3, p<
0.01 (**) relative to controls by student’s t-test.
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Figure 9. Dose response of OA-stimulated DAT pT53
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or no effect at lower doses of OA. According to the dose response curve the IC50 of OA
for T53 on DAT was indicated to be in the range of phosphatase PP1 (0.15 nM) (Fig.9).
Under our experimental conditions no visible effect was observed at IC50 values
corresponding to other phosphatases indicating PP1 as the potential phosphatase
dephosphorylating T53.
Psychostimulants differentially affect T53 phosphorylation on DAT
!

Psychostimulant drugs have been demonstrated to affect DAT function by
regulating DAT phosphorylation [77] [59]. To examine the effects of psychostimulant
DAT blockers and substrates on DAT pT53 levels, LLC-PK1 cells stably expressing rDAT
were treated with indicated drugs for 30 min using the phosphatase inhibitor, OA as
positive control (Fig.10). Cell lysates were immunoblotted with pT53 Ab, a phosphospecific antibody to detect phosphorylation of DAT specifically at T53 [69]. Western blot
analysis revealed that DAT displays pT53 under basal conditions as indicated in lane 1.
We observed that the psychostimulant substrate AMPH (lane 4) significantly stimulated
the DAT pT53 152 ± 9% of basal, (p<0.05) (Fig.10). Inhibition of protein phosphatases
with OA resulted in significant accumulation of pT53 levels, 177 ± 19% of basal,
(p<0.005) (Fig. 8 and 9). Interestingly, DAT blockers COC (110 ± 15% of basal) (lane2)
and BZT (93.5 ± 12.5% of basal) (lane 3) had no effect on pT53. The inability of both
psychostimulant (COC) and non-psychostimulant (BZT) DAT blockers to stimulate pT53
suggests that the stimulation of pT53 might be a substrate-specific effect. These results
demonstrate a differential response of psychostimulant substrates and blockers on DAT
pT53. Total DAT levels in the corresponding samples as recognized by MAb16 were
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Figure 10. Amphetamine stimulates phosphorylation at T53 on DAT
rDAT LLC-PK1 cells were treated with vehicle or 10 µM AMPH, BZT or 100 µM COC
or 1 µM OA for 30 min and cell lysates were immunoblotted with anti-pT53 Ab to detect
phosphorylation or MAb 16 to detect total DAT. The histogram shows pT53 staining
normalized for total DAT (means ± S.E.). n≥3, **p value< 0.0001 relative to basal.
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Figure 10. Amphetamine stimulates phosphorylation at T53 on DAT
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observed to be unaffected by the treatment conditions.
Psychostimulant substrates stimulate DAT T53 phosphorylation in a cocaine-dependent
manner
As DAT uptake blockers displayed no stimulatory effect on pT53 (Fig.10), we
questioned if stimulation of pT53 is a substrate-specific phenomenon. To investigate this,
we treated rDAT LLC-PK1 cells with the psychostimulant substrates AMPH, METH and
the endogenous substrate, DA for 30 min. The psychostimulant substrates stimulated
pT53 significantly, METH (159 ± 24% of basal, p<0.005); AMPH (142.4 ± 8% of basal,
p<0.05) as shown in Fig. 11. The endogenous substrate, DA showed a trend towards
increase in pT53 levels (125 ± 6% of basal) however, it was not found to be statistically
significant. These data indicated that the increase in DAT pT53 is a substrate-specific
phenomenon, with a significantly stronger effect observed with psychostimulant
substrates.
Amphetamines are lipophilic in nature and in addition to being transported via
DAT into cell, they can also diffuse through plasma membrane [81]. The next question
we addressed was, if the effect of AMPH on pT53 is a DAT-mediated effect. We
addressed this question by pretreating rDAT LLC-PK1 cells with 100 µM (-) cocaine,
followed by treatment with 10 µM AMPH therefore, preventing the entry of AMPH via
DAT. We observed the stimulatory effect of AMPH on pT53 (142 ± 8%, p<0.005)
(Fig.10 & 11). Similar to the observation in Fig.10, COC treatment alone on rDAT LLCPK1 cells did not cause any significant change in pT53 level (110 ± 15%) (Fig.12). In
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Figure 11. Psychostimulant substrates stimulate pT53
rDAT LLC-PK1 cells are treated with vehicle or 10 µM of the indicated drugs for 30 min
at 37°C. The cell lysates were immunoblotted with anti-pT53 (top) to detect
phosphorylation or MAb 16 (bottom) to detect total DAT. Histogram indicates the T53
phosphorylation normalized to total DAT (means ± S.E.). n=4, p<0.01 (**), <0.05 (*),
One-way ANOVA, with Tukeys’ post-hoc test.
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Figure 11. Psychostimulant substrates stimulate pT53
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Figure 12. Cocaine blocks amphetamine stimulated DAT pT53
rDAT LLC-PK1 cells were treated with vehicle or 10 µM AMPH for 30 min in the
absence or presence of 100 µM COC. COC pre-treatment was performed for 10 min
followed by additional 30 min with AMPH, and cell lysates were immunoblotted with
anti-pT53 to detect phosphorylation or MAb16 to detect total DAT. The histogram shows
the pT53 staining normalized for total DAT (means ± S.E.). n≥3, ***p value
<0.001relative to basal, One-way ANOVA, with Tukeys’ post-hoc test.
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Figure 12. Cocaine blocks amphetamine stimulated DAT pT53
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four independent experiments, each performed in duplicate, we observed that the AMPH
effect on pT53 was blocked when the cells were pre-treated with COC, displaying 97 ± 6
% of the basal pT53 level. Perturbing the entry of AMPH into the cell through DAT, but
not the diffusion through plasma membrane completely abolished the AMPH effect on
pT53. This showed that stimulation of pT53 by AMPH is a DAT-mediated effect.
Native tissue response differs from heterologous system in amphetamine effect
!

Psychostimulant substrates stimulate pT53 in a time-dependent fashion in cells
!

To analyze the time dependence of AMPH and METH on DAT pT53, we treated
LLC-PK1 rDAT cells with 10 µM AMPH or METH for the indicated time points and the
cell lysates were assayed for pT53. AMPH significantly increased pT53 at 30 min
(142±7.8% of basal, p<0.005) treatment and pT53 level was sustained for atleast 60 min
(139±7.6% of basal, p<0.05) (Fig.13A). Shorter time points tested (2, 5, 10, min) did not
show a significant effect (not shown). METH treatment stimulated a small yet significant
increase in pT53 at 2 min (121±7.1% of basal, p<0.05), and 30 min METH treatment
stimulated pT53 (131±4% of basal, p<0.005) (Fig.13B) to levels similar to that of AMPH
in cells.
Time course of METH-stimulated pT53 in rat striatal synaptosomes
!

Next, we sought to investigate the time dependence of stimulated pT53 levels in
native tissue. We performed a time course of METH treatment under ex vivo conditions,
in rat striatal synaptosomes. In contrast to, LLC-PK1 cells, METH treatment in rat striatal
synaptosomes produced a significant increase in pT53 within 60 sec (132 ± 3% of basal,
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Figure 13. Time course of amphetamine stimulated pT53
rDAT LLC-PK1 cells treated with vehicle or 10µM AMPH (A) or METH (B) for the
indicated times, were immunoblotted with pT53 Ab to detect phosphorylation or MAb 16
to detect total DAT. The graphs indicate summary of pT53 normalized to total DAT
(means ± S.E.). n≥3, **p value <0.005 relative to basal, *p value < 0.05 relative to basal,
one-way ANOVA, with Tukeys’ post-hoc test.
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Figure 13. Time course of amphetamine stimulated pT53
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Methamphetamine

Figure 14. Methamphetamine stimulates pT53 in rat striatal synaptosomes
Rat striatal synaptosomes were isolated and treated with 10 µM METH for the indicated
times at 30°C. Solubilized DATs were resolved by SDS-PAGE and transferred to PVDF.
Blots were probed with pT53Ab. Graph indicates T53 phosphorylation normalized to
total DAT (means ± S.E.). n≥3, **p value<0.005, *p value<0.05 relative to basal, oneway ANOVA, with Tukey’s post-hoc test.
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Figure 14. Methamphetamine stimulates pT53 in rat striatal synaptosomes
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p<0.005) after treatment and this increase was also observed at 10 min (128 ± 3% of
basal, p<0.005) (Fig.14), and the pT53 level sustained atleast 20 min (121 ± 7%) (data
not shown). This indicates psychostimulant drugs impart their effect on pT53 faster in
native tissue when compared with the heterologous expression system.
Methamphetamine but not cocaine stimulates pT53 in vivo
!

To investigate the differential regulation of psychostimulant drugs on pT53 in vivo, we
subcutaneously injected male Sprague-Dawley rats with 15 mg/kg METH; or COC or
saline for 30 min (Fig.15). After 30 min, the animals were then decapitated to remove the
striata and the striatal membranes were analyzed for pT53 levels and total DAT levels.
The saline injected animal displayed basal pT53 levels. COC-injected animals displayed
no effect on pT53 levels (Fig.15) similar to our results observed in the heterologous
expression system (Fig.13). METH-treated animals displayed a significant stimulation of
pT53 (Fig.15) compared to saline and COC injected animal. This further confirms the
differential regulation of psychostimulant drugs on pT53 both in a heterologous
expression (Fig.13) system and in vivo. MAb16 immunostaining displayed similar DAT
levels in saline and drug-injected animals indicating that treatment had no effect on total
DAT levels.
Methamphetamine time course in vivo
!

To further understand the effect of METH on pT53, we performed a time course of
METH treatment in vivo in male Sprague-Dawley rats. The animals were subcutaneously
(SC) injected with METH (15mg/kg) or saline and caged individually until decapitation.
After 10, 30 or 60 min post injection, the animals were decapitated and the brain was
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Figure 15. Methamphetamine but not cocaine stimulates pT53 in vivo
Male

Sprague-Dawley

rats

were

subcutaneously

injected

with

15mg/kg

of

methamphetamine (METH), 15 mg/kg cocaine (COC) or saline for 30 min. The animals
were decapitated and the brains were dissected to make striatal membranes which then
were subjected to immunoprecipitation with protein-A-sepharose cross-linked with pT53
Ab and the eluted sample was resolved by SDS-PAGE and transferred to PVDF. Blots
were probed with MAb16. Total DAT levels were determined by directly blotting lysates
with MAb16. The DAT pT53 was normalized to total DAT levels. Histogram indicates
the quantification of the immunoblots, (means ± S.E.). n=3, *p value<0.05 relative to
basal, one-way ANOVA,!with Tukey’s post-hoc test.
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Figure 15. Methamphetamine but not cocaine stimulates pT53 in vivo
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Figure 16. Methamphetamine stimulates pT53 in vivo in a time-dependent manner
Male

Sprague-Dawley

rats

were

subcutaneously

injected

with

15mg/kg

of

Methamphetamine (METH) for the indicated time points. The animals were decapitated
and the brains were dissected to make striatal membranes which then were subjected to
immunoprecipitation with protein-A-sepharose cross-linked with pT53 Ab and the eluted
sample was resolved by SDS-PAGE and transferred to PVDF. Blots were probed with
MAb16. The DAT pT53 was normalized to total DAT levels. Histogram indicates the
quantification of the immunoblots, (means ± S.E.). n≥3,! **p value<0.005, *p value<0.05
relative to basal, t-test.
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Figure 16. Methamphetamine stimulates pT53 in vivo in a time-dependent manner
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dissected to remove the rat striatum and the rat striatal membranes were analyzed for
pT53 levels. The saline control animals displayed a basal level of pT53 immunostaining
similar to the rDAT LLC-PK1 cells indicating the regulation of pT53 under physiological
conditions. We observed the stimulation of pT53 levels in METH-injected animals and
this effect occurred in a time-dependent fashion. The shortest in vivo time point tested
was 10 min, which displayed a significant stimulation of pT53 at 10 min (119 ± 3%,
p<0.005). The stimulation of pT53 was further increased at 30 min (129 ± 10%, p<0.005)
and the increased pT53 was sustained at 60 min (128 ± 10%, p<0.05) (Fig.16) indicating
the alteration of downstream signaling. The METH-injected animals were observed to be
visibly hyperactive compared to the saline control.
Pin1 inhibitor, juglone, stimulates pT53 in cells and in rat striatal synaptosomes
!

We hypothesized that Pin1 isomerizes cis-pThr53-Pro54 to trans-pThr53-Pro54
allowing dephosphorylation by conformation-specific phosphatases. To investigate our
hypothesis of Pin1 regulation of DAT, we used juglone (Jug), a small-molecule inhibitor
specific for Pin1. LLC-PK1 cells stably expressing rDAT were treated with Jug or DMSO
as control and the cell lysates were analyzed for pT53 and total DAT levels. Treatment of
LLC-PK1 cells stably expressing rDAT with Jug significantly increased pT53 at both 5
µM (162 ± 13%, p< 0.005) and 10 µM (128 ± 12%, p<0.05) (Fig.17) compared to the
control conditions. OA used as positive control stimulated pT53 120 ± 5%, p<0.005
compared to control. Jug-stimulated pT53 represents the accumulation of the cisconformation of the pThr53-Pro54 sequence that is inaccessible to the trans-conformation
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Figure 17. Pin1 regulates dephosphorylation of DAT T53 in LLC-PK1 cells and in rat
striatal synaptosomes
(A) rDAT LLC-PK1 cells or (B) rat striatal synaptosomes were treated with indicated
concentrations of Pin1 inhibitor, Juglone for 30 min at 30°C. The samples were then
solubilized with sample buffer and DAT was resolved with SDS-PAGE and transferred to
PVDF membrane. The pT53 signals were identified with pT53 Ab and total DAT levels
with MAb16. Histogram indicates phospho-T53 signals normalized to total DAT (means
± S.E.), n=3, ** p<0.005, ANOVA with Tukey’s post hoc test).
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A)

B)

Figure 17. Pin1 regulates dephosphorylation of DAT T53 in LLC-PK1 rDAT cells and in
rat striatal synaptosomes

-
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preferring phosphatases. This indicates post-phosphorylation regulation of DAT by the
prolyl isomerase, Pin1.
We investigated if Pin1 exhibited similar regulation on DAT in native tissue. To
analyze that, we treated rat striatal synaptosomes with Juglone or DMSO and measured
pT53 levels. The DMSO control revealed basal-level pT53, which was significantly
increased in the presence of Jug, both at 5 µM, 117 ± 3 %, p<0.05 and at 10 µM, 121 ± 4
%, p <0.005 compared to control. Activation of protein kinase C (PKC) by PMA, used a
positive control also stimulated pT53 133 ± 9 %, p<0.005, compared to control (Fig.17).
The total DAT levels were unaffected by the treatment conditions. This indicates the Pin1
regulates DAT pT53 in heterologous expression system and in rat striatal synaptosomes.
Our data reveals a novel pathway of DAT regulation by Pin1 via T53 phosphorylation.
Juglone stimulates [3H]DA efflux from rat striatal synaptosomes
We next explored the effect of Pin1 regulation on DAT function. Rat striatal
synaptosomes were treated with Jug and analyzed for basal [3H]DA efflux. We observed
a basal [3H]DA efflux in synaptosomes treated with DMSO. Jug treated rat striatal
synaptosomes exhibited a significant increase in [3H]DA efflux both at 5 min (211 ±
25%, p<0.005) and 15 min (203 ± 23%, p<0.005) (Fig.18) treatment time points
compared to the control conditions. The efflux observed was blocked by COC and
occurred in the absence of efflux-stimulating substances like amphetamine (AMPH). This
is the first observation to demonstrate a significant increase in basal efflux by a cis-trans
prolyl isomerase inhibitor. We observed that under the same conditions, DAT uptake
activity from rat striatal synaptosomes was not significantly altered by Jug (data not
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shown) suggesting that Jug effect on DAT function could potentially be altering DAT
conformation to an efflux promoting state.
Juglone stimulates pERK
!

We next explored the pathway of Jug-stimulated efflux in rat striatal
synaptosomes. Jug stimulates pT53 (Fig.17) in rat striatal synaptosomes and T53 has
been demonstrated to be a substrate for proline-directed kinases such as ERK [44]. We
analyzed the rat striatal synaptosomal sample for increase in phosphorylated ERK
(pERK). The rat striatal synaptosomes revealed a basal pERK signal, which was
significantly increased in rat striatal synaptosomes treated with Jug for both 5 min
(196%±22, p<0.005) and 15 min (175±23%, p<0.05) compared to DMSO treated control
(Fig.19). This suggests that Pin1 also regulates the function of ERK by cis-trans
isomerization of proline-directed phosphorylation sites on ERK required for its
activation. Immunostaining with ERKAb revealed that total ERK levels were unaffected
under the experimental conditions indicating that Jug stimulates pERK without affecting
the total ERK levels. This suggests that Jug-stimulated [3H]DA efflux could be achieved
via pERK mediated phosphorylation of T53 on DAT.
Pin1 interacts with the N-terminus of DAT
!

Our next step was to investigate the interaction between Pin1 and DAT. We
recombinantly expressed the N-terminus of DAT (N-DAT) in E.coli and purified the
peptides as described in [44]. ELISA was performed using N-DAT as bait and
recombinant Pin1 as prey and vice-versa. The colorimetric density was used as a
measure of interaction between N-DAT and Pin1 (Fig.20). We observed a strong
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interaction between N-DAT and Pin1, occurs in a dose-dependent manner (data not
shown). Our ELISA data demonstrates the prolyl isomerase, Pin1 as a new interaction
partner of DAT (Fig.20), which regulates the mechanism of DAT mediated [3H]DA
efflux

and

also

the

conformational

state

dephosphorylation.!
!
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of

pT53,

thereby

dictating

its

Figure 18. Juglone stimulates [3H]DA efflux in rat striatal synaptosomes
Rat striatal synaptosomes were loaded with [3H]DA for 5 min at 30°C followed by
treatment with Jug for 5 and 15 min at 30°C. The synaptosomes were immediately
centrifuged at 4°C at 17000xg for 12 min and the supernatant was analyzed for [3H]DA
efflux. Jug significantly increased [3H]DA efflux from rat striatal synaptosomes at both 5
and 15 min, ** p<0.005, n (4), one-way ANOVA, tukey’s post-hoc test.
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Figure 18. Juglone stimulates [3H]DA efflux in rat striatal synaptosomes
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Figure 19. Juglone activates ERK
Jug-treated rat striatal synaptosomes were immunoblotted with pERK Ab and ERK Ab to
analyze the levels of activated ERK and total ERK respectively. Inhibition of Pin1 by Jug
significantly increased pERK compared to control, ** p<0.005 and * p<0.05, n (4), oneway ANOVA, tukey’s post-hoc test. Histogram demonstrates the quantification of pERK
normalized to total ERK.
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Figure 19. Juglone activates ERK
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Figure 20. Pin1 interacts with the N-terminus of DAT
ELISA was performed as described in methods. Briefly, recombinantly expressed Nterminus of DAT (N-DAT, 10 µg/ml) was used as bait and recombinant Pin1, (10 µg/ml)
was used as prey. PNPP was used as substrate for colorimetric analysis. The absorbance
was measured at 405 nm revealing the interaction between N-DAT and Pin, n=3.
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Figure 20. Pin1 interacts with the N-terminus of DAT!
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CHAPTER IV
!

DISCUSSION
!

Psychostimulant substrate regulation of DAT T53 phosphorylation
!

Our study demonstrates the differential effect of psychostimulant drugs on pT53,
a proline-directed phosphorylation site on the DAT N-terminus. Psychostimulant
substrates like AMPH and METH were observed to increase pT53 in a heterologous
expression system, rat striatal preparations and under in vivo conditions. Uptake blockers
tested including COC, BZT were not capable of this stimulatory effect nor did they affect
basal pT53 levels. Although AMPH and METH have been shown to stimulate PKCmediated DAT phosphorylation, the majority of which occurs at the serine cluster at the
N-terminus [59], this is the first evidence to demonstrate a differential effect of
psychostimulant substrates and blockers on the proline-directed phosphorylation site on
DAT. Proline-directed kinases such as ERK regulation of DAT activity via dopamine
receptor mediated mechanisms [56], [57] have been shown. However, our findings unveil
a direct regulation of DAT by proline-directed kinases via T53.
We have also identified a novel regulatory pathway of DAT function by a
peptidyl prolyl cis-trans isomerase, Pin1. A small molecule inhibitor of Pin1, Jug
significantly increases pT53 in both a heterologous expression system and in rat striatal
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synaptosomes. In addition, we also observed that Pin1 regulates the efflux mechanism of
DAT in rat striatal synaptosomes potentially via direct interaction between N-DAT and
Pin1.
Inhibition of phosphatases by OA has always produced the highest level of DAT
phosphorylation indicating the continuous activity of the physiological system to
maintain a non-phosphorylated DAT state. In attempts to identify the phosphatase acting
at T53 we performed dose response of OA in rat striatal synaptosomes and a heterologous
cell system. OA dose response performed in rat striatal synaptosomes and the
heterologous system both indicated PP1 to be the likely phosphatase involved in T53
regulation. No effect was seen at lower doses of OA that corresponds to inhibit PP2A
ruling out PP2A as the phosphatase acting at T53 under the conditions we tested. PP1 has
been shown to be the primary phosphatase involved in DAT phosphorylation regulation
although PP2A inhibitor also showed a significant increase in DAT phosphorylation [82].
It is possible that our experimental conditions or detection by western blot was not
sensitive enough to detect an effect present at lower doses of OA. Further research with
specific phosphatase inhibitors is required to approach this aspect.
The AMPH effect on DAT T53 phosphorylation is either due to binding to or
transport through DAT as COC blockade of DAT prior to AMPH treatment in LLC-PK1rDAT abolishes the AMPH effect. This is in accordance with the METH effect on the
DAT phosphorylation which was also blocked by COC pre-treatment [59]. This indicates
that the AMPH effect on DAT phosphorylation is not due to diffusion of AMPH through
the plasma membrane but DAT-dependent. COC by itself did not influence both overall
DAT phosphorylation (48) as well as T53 phosphorylation.
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The time dependence of pT53 stimulated by AMPH in a heterologous expression
system and in striatal synaptosomes produced interesting results. AMPH treatment of
LLC-PK1- rDAT showed a significant increase in T53 phosphorylation only after 30 min
treatment and was sustained until 60 min. The shorter time points (5-20 min) did not
affect the basal T53 phosphorylation. However in rat striatal synaptosomes METH
caused a significant increase in DAT T53 phosphorylation as short as 60 sec. This is the
first evidence so far for a rapid phosphorylational stimulation by a psychostimulant.
METH effect on T53 phosphorylation remained significant until 10 min and the next time
point tested (20 min) does not show a significant effect. It is interesting to note that the
METH effect on overall DAT phosphorylation which was observed to be on the serinecluster of the N-terminus is significant only at 10 and 15 min treatment [59]. METH
induced DAT T53 phosphorylation might be one of the initial steps followed by serinecluster phosphorylation. Since the METH-effect on T53 is instantaneous, it might be
affecting the transport kinetics or interaction of DAT with other proteins that facilitate or
affect function of DAT downstream.
We have previously reported in both the heterologous expression system and in
rat striatal tissue that, T53 displays basal level phosphorylation which is stimulated in the
presence PMA and OA [69] and by psychostimulant substrates as indicated in our current
study (Fig.1, and 6). Our previous studies revealed that T53A rDAT (phosphorylationdeficient mutant) and T53D rDAT (phospho-mimetic mutant), had impaired [3H]DA
uptake activity compared to WT rDAT. Also, both T53A rDAT and T53D rDAT
displayed no detectable AMPH-stimulated [3H]MPP+ release [69]. The similar functional
pattern of both T53A and T53D rDAT suggested that it is not just the negative charge
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imparted by the phosphorylation rather a potential conformational change associated with
the pT53 that is crucial for the DAT function. Another N-terminal mutant, T62D DAT
has been reported to display altered DA uptake and efflux indicating the structural and
functional importance of the N-terminus [70].
Amphetamines are also known to impact the surface expression of DAT in a
biphasic manner, which was observed to be cocaine-sensitive. In both rat striatal
synaptosomes and a cell system treated with AMPH increased the surface expression of
DAT within 30-60 sec and remained till 60 sec along with an increase in efflux [41], [83]
but, AMPH treatment for 30 min decreased the surface expression of DAT [40]. METHinduced T53 phosphorylation that fades at later time points might be associated with the
biphasic phenomenon observed in the regulation of surface expression of DAT by
AMPH.
Neuronal proteins like syntaxin 1A (Syn 1A) have been found to affect DAT
function and phosphorylation. Treatment of Syn 1A protease Botulinum Neurotoxin C
(BoNT/C) increases DAT phosphorylation in rat striatal tissue along with an increase in
uptake [35]. Syn 1A interacts with the N-terminus of DAT (1-33 aa of DAT) which is
stimulated in the presence of AMPH [36]. Expression of Syn 1A in hDAT expressing
cells potentiated AMPH-stimulated efflux. Interestingly, inhibition of CAMKII, the
activity of which was observed to be required for AMPH-stimulated efflux [62],
abolished the Syn 1A stimulated AMPH efflux. Such events are also observed in other
transporters like NET. The AMPH-stimulated association and surface expression of Syn
1A with NET was inhibited with CAMKII inhibitor [75]. This suggests the AMPH
induced phosphorylation might promote the association of proteins like Syn 1A with the
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transporters to further regulate transporter function and surface expression. AMPHinduced T53 phosphorylation on DAT might also be following a similar mechanism
although further research is required to address if any protein associations are affected.
Recombinantly expressed N-DAT was phosphorylated by PKC, PKA and prolinedirected kinases like ERK, JNK and p38. Phosphoamino acid analysis of rDAT indicated
that T53 was strongly phosphorylated by proline-directed kinases like ERK, JNK and p38
[44]. Our attempts to identify the proline-directed kinase involved in regulation of T53
phosphorylation in striatal synaptosomes did not provide supporting results. Though the
inhibitors used were membrane permeable, we assume that the inhibitors were not
accessible in the treatment time or the western blot employed was not sensitive to detect
the effects. However it is noteworthy to mention that PKC activator PMA treatment both
in heterologous system and rat striatal synaptosomes stimulated the T53 phosphorylation
significantly.
Post-phosphorylation control of DAT function by peptidyl prolyl cis-trans isomerase,
Pin1
!

In this study, we identified a novel regulatory pathway of DAT by the peptidyl
prolyl cis-trans isomerase Pin1, potentially dictating the cis-trans isomerization of pT53
on the N-terminus of DAT. This is the first study to show DAT regulation by Pin1,
which, has been associated with several pathological conditions including cancer and
Alzheimer’s disease.
Pin1 has been demonstrated to catalyze the isomerization of pSer/Thr-Pro
peptides from cis to trans configuration in several proteins. Restoration of
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hyperphosphorylated tau (ptau) protein to the trans conformation by Pin1 is required for
dephosphorylation, as phosphatases like PP2A have been shown to prefer trans
configuration [72]. Consistent with these studies, our data revealed that inhibition of Pin1
using juglone (Jug), thereby preventing cis to trans isomerization, significantly increased
the pT53 on DAT in both a heterologous expression system and in rat striatal tissue. The
increase in pT53 observed was in the absence of any stimulating conditions like kinase
activators or phosphatase inhibitors or psychostimulant substrates. This is the first
evidence to demonstrate that isomerization of cis-pT53 to trans-pT53 on DAT by Pin1 is
required for dephosphorylation. Recombinantly expressed N-terminus of DAT (N-DAT),
phosphorylated by ERK was shown to be resistant to dephosphorylation in vitro by either
of the phosphatases; PP2A or PP1 [44] consistent with our studies indicating the
importance of Pin1 catalyzed post-phosphorylation cis-trans conformational change for
dephosphorylation. The major Ser/Thr phosphatase, PP2A has been shown to interact
with the N-terminus of DAT [33] in a structural proximity to potentially dephosphorylate
T53 on the N-terminus of DAT post the Pin1 catalysis. PP2A whose activity on its
substrates is regulated by Pin1 is known to interact with DAT (site), which leads one to
speculate a possible effect of Pin1 on DAT.
Proline-directed kinase, ERK has been shown to regulate DAT uptake via DA
receptor-mediated mechanism [56], [57]. Treatment of rat striatal synaptosomes with Jug
caused a tremendous increase in [3H]DA efflux compared to control conditions. This
increased efflux was observed in the absence of amphetamine, a classic inducer of efflux.
To our knowledge, this is the first evidence demonstrating a direct role for prolinedirected phosphorylation on the DAT efflux mechanism. This finding further confirms
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that Pin1 catalyzed conformational change is required for the efflux mechanism as our
previous studies have demonstrated the inability of T53D rDAT to efflux [69]. We
observed that uptake activity was not altered under the same conditions in rat striatal
synaptosomes. Jug stimulated efflux in rat striatal synaptosomes was associated with
significant increase in pERK levels compared to control. This suggests that Jugstimulated efflux observed in the rat striatal synaptosomes potentially could be mediated
through pERK phosphorylation of T53 on DAT. We are not ruling out the possibility that
Jug-mediated [3H]DA efflux could be through its action on another neuronal protein as
Pin1 is known to impact several neuronal proteins like tau, neurofilaments [73], [84], [85]
and also other kinases like JNK [86]. In addition, T53 on the N-terminus of DAT is
localized in close proximity to TM1, which forms one of the components of the substrate
translocation pathway. The pT53 on DAT with its Pin1 catalyzed conformational
rearrangement, might impact TM1, the substrate permeation pathway component and the
putative intracellular gate residue R60, thereby potentially influencing DAT function.
Our ELISA data indicated interaction of Pin1 with N-DAT peptide (Fig.20). This
suggests that the effect of Jug, on [3H]DA efflux mechanism could be due to the direct
interaction between Pin1 and N-DAT through isomerization inhibition of pThr53-Pro.
The AMPH-stimulated efflux has been shown to be affected by several DAT interaction
partners including Syn 1A, and Flotillin [36][39]. Pin1, by regulating the conformation of
pThr53-Pro, which also lies in the SH3 domain ligand (P-P-X-X-P), could potentially
control the interaction of other scaffolding proteins and their regulation of DAT function.
We observed that the total amount of DAT was not affected by Jug under our
experimental conditions.
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DAT and diseases
!

Dopaminergic signaling has been implicated in several severe pathological
conditions including ADHD (Attention deficit hyperactive disorder), Schizophrenia,
Tourette syndrome, bipolar disorder and Parkinson’s disease (PD). DAT polymorphisms
and death of the dopaminergic neurons are some of the characteristics of a few disease
states, strongly implying the importance of dopamine homeostasis for normal
physiological function.
In the case of ADHD, a wide set of DAT polymorphisms both in the coding
regions and the intronic regions have been reported in humans, some of which are
A559V, R615C, V382A, V55A, E602G hDATs [87][88][89]. A bipolar disorder patient
and two male siblings diagnosed with ADHD have been reported to have the A559V
hDAT mutation [90]. These polymorphisms, when cloned into heterologous expression
systems displayed abnormal DAT functionalities. A559V hDAT displayed a ~ 300%
increase in spontaneous DA efflux compared to WT DAT. This is referred to as
anomalous DA efflux (ADE). This indicates the ability of a point mutation to
significantly affect DAT function potentially by altering the conformation of the substrate
translocation pathway of DAT.
The role of DA D2 auto-receptors (D2R) in mediating the ADE of A559V hDAT
was demonstrated in 2010 [87]. The ADE displayed by A559V hDAT is thereby
mediated through D2R activation of CaMKII catalyzed phosphorylation of N-terminal
serines [87]. D2R-mediated DAT regulation by MAPK has been previously demonstrated
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[57]. This data demonstrated the involvement of phosphorylation of the DAT N-terminus
to play a crucial role in pathological conditions.
R615C DAT, another ADHD associated mutant had significant reduction in
surface expression with AMPH-stimulated efflux comparable to WT DAT.
Coimmunoprecipitation studies demonstrated that R615C DAT-CaMKII complexes were
significantly enhanced relative to WT DAT-CaMKII complexes. The [32P] Labeling of
R615C DAT displayed significantly increased basal phosphorylation compared to WT
DAT [91].
Pin1 has been shown to promote APP degradation in AD [92] by inhibiting
GSK3β thereby reducing the levels of amyloid beta [93]. The notable feature of ADaffected neurons is the depletion of soluble Pin1. Pin1 has been shown to facilitate the
dephosphorylation of tau protein by PP2A showcasing the presence of a postphosphorylation regulatory step that restores the function [72][73]. This indicates an
additional regulatory step for phosphoproteins that might dictate its function or
subcellular localization.
Our data culminates to the point that Pin1 regulates the DAT efflux mechanism
potentially through isomerization of p53 on DAT. All of this experimental evidence
extends

our

understanding

of

psychostimulant

substrate

regulation

of

DAT

phosphorylation at the proline-directed phosphorylation site, T53. Also, we revealed a
novel pathway of DAT regulation by the isomerase Pin1, which could be exploited to
understand DAT regulation under both physiological and pathological states.
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